Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at Wall Street Zen

Investment analysts at Wall Street Zen initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued to investors on Wednesday. The firm set a "hold" rating on the medical research company's stock.

Several other research analysts have also commented on CTSO. D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a report on Thursday, May 15th. HC Wainwright restated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th.

Cytosorbents Stock Performance

NASDAQ CTSO traded down $0.00 during trading hours on Wednesday, hitting $0.85. 52,325 shares of the stock were exchanged, compared to its average volume of 146,513. The company has a market cap of $52.91 million, a price-to-earnings ratio of -2.35 and a beta of 1.17. The stock has a 50-day moving average of $0.97 and a 200 day moving average of $0.99. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. As a group, equities research analysts forecast that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors have recently made changes to their positions in CTSO. Millennium Management LLC acquired a new position in Cytosorbents during the 4th quarter valued at approximately $30,000. Goldman Sachs Group Inc. boosted its holdings in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after acquiring an additional 37,519 shares during the period. Key Client Fiduciary Advisors LLC grew its position in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after acquiring an additional 43,900 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after acquiring an additional 16,701 shares during the period. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.